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Abstract Introduction
We examined the molecular defect in two kindreds with
"variant" X-linked chronic granulomatous disease (CGD).
Western blots of neutrophil extracts showed decreased im-
munoreactive cytochrome bssn components gp91-phox and
p22-phox. Analysis of mRNA demonstrated reduced gp91-
phox transcripts, with relative preservation ofan alternative
mRNA species created by transcription initiation in the
third exon of the gene. Single strand conformation polymor-
phism analysis of the 5' flanking region of the patients'
gp91-phox genes revealed an electrophoretic abnormality
not detected in 40 other gp91-phox genes. Genomic sequenc-
ing demonstrated a single base change associated with CGD
in each kindred: in one, adenine to cytosine at base pair -
57 and in the other, thymidine to cytosine at -55. These
mutations are located between the "CCAAT" and
"TATA" box consensus sequences involved in eukaryotic
gene transcription. Gel shift assays revealed two specific
DNA-protein complexes formed between phagocyte nuclear
extracts and an oligonucleotide probe representing bases
-31 to -68 of the gp91-phox promoter region; the faster-
migrating complex could not be formed with oligonucleo-
tides containing either of the promoter mutations. Thus,
these promoter region mutations appear to be causally re-
lated to the loss of association of a DNA-binding protein
and lead to diminihed gp91-phox expression, abnormal
transcription initiation, and the development of CGD. (J.
Clin. Invest. 1994.94:1205-1211.) Key words: DNA-binding
proteins * gene expression regulation * phagocytes * heredi-
tary diseases * point mutation
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Chronic granulomatous disease (CGD)' is an uncommon hered-
itary disorder characterized by recurrent pyogenic infections
which usually present early in life and may lead to death in
childhood (1-4). Phagocytes from CGD patients display nor-
mal chemotaxis, ingestion, and degranulation; but microbial
killing is deficient (5). The underlying biochemical defect is the
failure of a membrane-associated NADPH oxidase to produce
superoxide and related toxic oxygen metabolites (6, 7).
The phagocyte NADPH oxidase contains a low-midpoint-
potential b-cytochrome as the terminal electron donor. This
heme protein, cytochrome b558, is a heterodimer of a 91 -kD
glycoprotein component of the phagocyte oxidase (gp9l-phox)
and a 22-kD nonglycosylated polypeptide (p22-phox) (8). The
gene for gp91-phox was one of the first to be identified by
positional cloning (9) following localization to X chromosome
band Xp2l.1 (10). Hence, CGD kindreds with the gp9l-phox
component affected show X-linked inheritance (11, 12) and in
most cases the cytochrome b558 is reduced or absent from their
phagocytes (13).
The gene encoding gp91-phox encompasses 13 exons span-
ning - 30 kb of human X chromosome genomic DNA (14).
Multiple molecular defects producing X-linked CGD have been
identified within the coding region and introns of the gene ( 15-
21). Such mutations include large, multigene deletions, smaller
deletions and insertions, missense and nonsense substitutions,
and splicing defects. In 58% of X-linked CGD kindreds (28 of
48 tested), phagocytes express diminished levels of gp9l-phox
mRNA (Curnutte, J. T., and P. E. Newburger, manuscript in
preparation.); yet, for most such patients, no molecular defects
have been identified in PCR-amplified genomic DNA encoding
gp9l-phox gene exons (J. T. Curnutte, P. J. Hopkins, and
P. E. Newburger, unpublished data).
We have recently identified two kindreds with an unusual
form of X-linked CGD (22) and reported in detail the clinical
and biochemical characteristics of their phagocytes.2 In the ma-
jority of patients with CGD, phagocytes completely lack cyto-
chrome b and exhibit no detectable oxidase activity. Occasional,
"variant" forms of X-linked CGD occur, in which low levels
(1-25% of normal) of cytochrome b and proportionately de-
creased oxidase activity are expressed uniformly in all phago-
1. Abbreviations used in this paper: CGD, chronic granulomatous dis-
ease; gp9l-phox, 91 kD glycoprotein component of the phagocyte oxi-
dase; p22-phox, 22 kD protein component of the phagocyte oxidase;
RACE, rapid amplification of cDNA ends; SSCP, single strand confor-
mation polymorphism.
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cytes (23-27). However, in the two kindreds of the present
study, a small subset (5-10%) of neutrophils expressed near
normal levels of cytochrome b and oxidase activity, while the
remaining cells completely lacked both. Hence the pooled cell
oxidase activity was 5-10% of normal, as seen in other forms
of "variant" CGD, but the cellular distribution was distinctly
different. X-linked inheritance was established by maternal car-
rier testing. Cytogenetic and restriction fragment length poly-
morphism analysis demonstrated X chromosome hemizygosity
and thus ruled out a sex chromosome abnormality with random
X chromosome inactivation as a cause for the observed distribu-
tion of activity. Thus, we hypothesized a genetic defect in gp9l-
phox gene regulation as the cause for this form of CGD.
We have investigated the molecular basis of this apparent
defect in the regulation of gp9l-phox expression, and now re-
port two neighboring mutations in the upstream promoter region
of the gp9l-phox gene in these kindreds. Both mutations pre-
vent the association of an unidentified DNA-binding protein
with oligonucleotide sequences from the promoter region. The
functional consequences of the promoter region mutations are
impaired transcription of the gp9l-phox gene and utilization,
at a decreased rate, of an alternative downstream transcription
start site.
Methods
Subjects. The clinical and biochemical characterization of the CGD
patients reported in this study have been previously reported in abstract
form (22, 28) and in detail elsewhere.2
Procedures and consent forms were approved by the Committees on
the Protection of Human Subjects in Research of the University of
Massachusetts Medical Center and The Scripps Research Institute.
Western blots. Immunoreactive quantitation of gp91-phox and p22-
phox in diisopropylfluorophosphate-treated granulocyte extracts was
performed by Western blotting, using previously reported antisera and
methodology (29, 30). Extracts were prepared from the membrane frac-
tion of Percoll gradients (31) and 10 mg from each sample used per
lane for polyacrylamide gel electrophoresis.
Northern blots. Mixed mononuclear cells were isolated from citrate-
anticoagulated whole blood by ficoll-hypaque centrifugation (32). Total
cell RNA was extracted from the cells by the guanidine-HCl method
(33) and analyzed by Northern blots performed according to standard
procedures (34). Hybridization probes were full-length cDNAs for the
human gp91-phox (9), p22-phox (35) (kindly provided by Dr. M.
Dinauer, Indiana University Medical Center). Procedures for sequential
cycles of prehybridization, hybridization, washes, and filter stripping
were performed as described by Gatti, Concannon, and Salser (36).
Equal loading of lanes was demonstrated by examination of gels after
ethidium bromide staining and by rehybridization with a 5.8-kb HindmIl
restriction fragment of rat 18S ribosomal DNA (37).
Band densitometry was performed by computer image analysis of the
integrated optical density of autoradiograph bands, using ImageMeasure
software (Microscience, Inc., Federal Way, WA) on an Epson Equity
III+ computer, or by direct measurement of 32P decay on a Betascope
603 (Betagen, Waltham, MA) blot analyzer.
Single-strand conformation polymorphism (SSCP) analysis. Geno-
mic DNA was extracted from peripheral blood (34) and analyzed by
SSCP as previously described (38, 39) using two-stage nested primer
PCR with outer 20-bp oligonucleotide primers with 0.1 g of genomic
DNA, then inner primers end-labeled with 32p with the first PCR prod-
ucts as template. The resultant labeled PCR products were visualized
by polyacrylamide gel electrophoresis and autoradiography. SSCP anal-
ysis was performed on the 5' flanking region and all 13 exons of the
gp91-phox gene.
5' end mapping ofmRNA transcripts. We adapted the reagents and
procedures from the Clontech, Inc. (Palo Alto, CA) 5 '-Ampli-
FINDER' RACE (rapid amplification of cDNA ends) Kit (40, 41).
The basic strategy was to prepare B cell line polyadenylated RNA (34),
reverse transcribe from a primer specific to gp9l-phox nucleotides 600-
634, anneal an anchor to the 5' end of the resultant cDNA by single-
stranded ligation with T4 RNA ligase in the presence of hexamine cobalt
chloride (42), and then PCR amplify the ligation product using an
anchor-specific forward primer and successive nested reverse primers
corresponding to nucleotides 417-434 and 375-405. The PCR products
were analyzed by agarose gel electrophoresis and sequenced after sub-
cloning into pBluescript (Stratagene, La Jolla, CA).
DNA sequencing. Genomic DNA was isolated from peripheral blood
leukocytes by standard methods (34) and amplified by PCR using syn-
thetic oligonucleotide primers designed to amplify the 5 '-flanking region
or each of the first 12 (coding region) exons of the gp9l-phox gene.
Alternatively, coding region segments were amplified from cDNA pre-
pared by reverse transcription (Pharmacia First-Strand cDNA Synthesis
Kit; Pharmacia Fine Chemicals, Piscataway, NJ) of mononuclear cell
RNA, prepared as above. Amplified segments were subcloned into
pUC19 or related plasmids and bidirectional dideoxy sequencing of the
double-stranded DNA was performed by standard methods (34).
DNA sequence data were repetitively confirmed by sequencing the
same segments ofDNA in different laboratories (Scripps and University
of Massachusetts) using different PCR primers.
Gel shift assays. The myelomonoblastic PLB985 cell line (43) was
the generous gift of Thomas Rado (Department of Medicine, University
of Alabama at Birmingham). These cells were grown in RPMI medium
supplemented with 10% fetal calf serum, 0.2 mM glutamate, 50 U/ml
penicillin, and 50 ttg/ml streptomycin. Differentiation of PLB985 cells
along the granulocytic lineage was performed by the addition of 1
,OM retinoic acid for 24 h followed by 60 mM dimethylformamide
for 24 h.
Nuclear extracts were prepared as described by Dignam et al. (44).
Complementary oligonucleotides were annealed and end-labeled with
[y-32P]ATP as previously described (14). All oligonucleotides were
synthesized so that annealed strands contain BamHI overhangs at their
ends. Gel shift assays were carried out by adding nuclear extract (3-5
,0g) to 18 ul of buffer [10 mM Tris (pH 7.5), 50 mM K-glutamate, 5
mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol, 50 mM
poly[d(IC)], and competitor double-stranded oligonucleotides where
indicated], and the mixture was preincubated on ice for 15 min. Approx-
imately 5-10 x 103 dpm of probe was then added to each sample and
incubation on ice was continued for 15 min. Samples were loaded onto
a 0.5x TBE [45 mM Tris (pH 8.3), 45 mM borate, 1.25 mM EDTA],
3.5% nondenaturing polyacrylamide gel, and electrophoresis was carried
out at 4°C until the free probe was at the bottom of the gel. Gels were
then dried and autoradiography was performed.
Results
We studied one patient (here designated P) from one kindred
and two brothers (designated Bl and B2) from another, unre-
lated kindred with an unusual form of CGD with low levels of
residual oxidase activity (22). The clinical and biochemical
characterization of these CGD patients are reported in detail
elsewhere.2
To investigate levels of cytochrome b558 protein compo-
nents, we examined western blots of neutrophil extracts, illus-
trated in Fig. 1. Normal neutrophils (lanes 1, 4, and 8) contained
both gp9l-phox (a) and p22-phox (b); whereas cytochrome b-
negative CGD neutrophils (lanes 2 and 7) contained neither.
In CGD patients P, B 1, and B2 (lanes 3, 5, and 6, respectively),
2. Woodman, R. C., P. E. Newburger, P. Anklesaria, M. S. Cohen, and
J. T. Curnutte, manuscript submitted for publication.
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Figure 1. Western blot of immunoreactive gp9l-phox and p22-phox
protein. Lanes 1, 4, and 8: Neutrophil extracts from normal donors;
lanes 2 and 7, from cytochrome b-negative CGD patients; lane 3, from
patient P; lane 5, from patient B1; lane 6, from patient B2. (a), Neutro-
phil extracts probed with antibody against gp9l-phox, detected as a
wide band at the indicated position. (b), Neutrophil extracts probed
with antibody against p22-phox, detected at the indicated position. 10
,4g protein loaded per lane.
neutrophils showed markedly decreased, but detectable, levels
of immunoreactive gp9l-phox and p22-phox. These results in-
dicate that the patients have a cytochrome b negative form
of CGD, with slight retention of immunoreactive cytochrome
components consistent with the low residual oxidase activity in
the cells. However, deficiency of either cytochrome component
destabilizes the other member of the heterodimer (45), so the
Western blot results are equally consistent with an X-linked
defect in the gene encoding gp9l-phox production or with au-
tosomal mutations in both alleles of the p22-phox gene.
Northern blot analysis demonstrated the levels of gp9l-phox
mRNA transcripts in the patients' and normal peripheral blood
mononuclear cells. As shown in Fig. 2 a gp91-phox expression
was reduced in the patients' cells, compared to the normal con-
trol lane at the far right. The Northern blot hybridization of full
length gp9l-phox cDNA probe to each patient's RNA showed
a relative preservation of a slightly more rapidly migrating tran-
script that is usually overshadowed by the predominant larger
4.7-kb band in RNA from normal phagocytes. It is best illus-
trated in autoradiograph in Fig. 2 b, which represents a Northern
blot of RNA analyzed by long duration, low voltage electropho-
resis in an 0.8% agarose-formaldehyde gel to maximize separa-
tion of the two bands.
All three patients' mononuclear cells expressed normal lev-
els of mRNA for p22-phox, the other component of the cyto-
chrome b558 heterodimer, shown in Fig. 2. HeLa cell RNA,
which served as a negative control for gp9l-phox expression,
demonstrates transcripts for p22-phox, which is expressed in a
wide variety of nonphagocytic cells (35).
In order to investigate the nature of the shorter transcript
that was preferentially expressed in the CGD cells, we amplified
Figure 2. Northern blot of gp9l-phox and p22-phox mRNA transcripts.
Each lane contained 10 o.g total cellular RNA from peripheral blood
mononuclear cells of the indicated donors or HeLa cell cultures, as
indicated. a shows a blot probed with 32P-labeled full length gp9l-phox
cDNA, then stripped and reprobed with p22-phox cDNA. b shows a
similar blot, probed only for gp9l-phox transcripts, of a gel run under
conditions (see text) designed to maximize resolution of the two tran-
script sizes. The thick arrows indicate the position of the normally
predominant, larger transcript; the thin arrows indicate the normally
minor, smaller transcript.
segments of cDNA produced by reverse transcription of RNA
from each patient. We utilized lymphoblastoid B cell lines cre-
ated by Epstein-Barr virus infection of the patients' peripheral
blood lymphocytes in order to harvest enough RNA for purifi-
cation of the polyadenylated RNA fraction, which is enriched
in messenger RNA. B cell lines from normal individuals express
phagocyte oxidase activity; but those derived from CGD pa-
tients show biochemical and molecular defects similar to those
of the patients' phagocytes (46). Thus, they can serve as in
vitro models of CGD cells and as sources for large harvests of
CGD patient nucleic acid. We confirmed that Northern blots
from these cells showed the same pattern of gp91-phox expres-
sion as that observed from fresh peripheral blood mononuclear
cells (data not shown). All PCR products from primers corre-
sponding to the gp91-phox cDNA sequence were normal in
size. We next amplified the 5' ends of the transcripts by utilizing
a forward primer corresponding to an anchor annealed to the
5' end of each cDNA. The resultant products, shown in Fig. 3,
demonstrated that an alternative transcript, - 200 bp shorter
than normal, was expressed along with the normal product in
B cell lines from each kindred. The shorter product, which was
NI P B2 bp
-1000
Figure 3. 5' ends of gp9l-phox mRNA -700
transcripts. 5 'RACE PCR products of - 600
gp9l-phox transcripts from the normal -400
(Ni) or CGD (P and B2) B cell lines - 300
were electrophoresed in a 3% agarose gel -200
and stained with ethidium bromide. The
right margin indicates the positions of
DNA size markers run in parallel.
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quences.
barely detectable in normal cells, appeared at greater or equal
proportion to the normal product in the patient samples. These
results were confirmed by 5' RACE analysis of whole cell RNA
extracts from peripheral blood mononuclear cells.
Sequencing of the short PCR products showed, as in the
example presented in Fig. 4, gp91-phox sequence starting at
nucleotide 190, then a guanine residue, followed by the ligated
anchor sequence. This finding indicates that transcription of this
mRNA species began at an alternative initiation site (cDNA
nucleotide 190) within the third exon of the gp91-phox gene
and was normally capped with a guanine residue at the 5'
end (47). Some 5 'RACE amplifications from members of each
kindred also produced a less abundant, shorter product begin-
ning at cDNA nucleotide 255, also within the third exon.
To determine whether mutations in the regulatory region of
the gp91-phox gene could be responsible for its diminished
expression in these patients, we screened the 5' (upstream)
flanking region of the gene by single strand conformation poly-
morphism (SSCP) analysis of PCR-amplified genomic DNA.
As shown in Fig. 5, single strand electrophoretic mobility of
this segment of gp9l-phox genes from patients B1 and B2, but
not P, differed from normal (lane N) and from patterns seen in
1 2 PBB3 4 5 6 7 8 9N
Figure 5. SSCP analysis of the 5' flanking region of the gp9l-phox
gene. SSCP analysis was performed, as described in Methods, on geno-
mic DNA extracted from peripheral blood leukocytes. The gel mobility
of resultant 32P-labeled PCR products was visualized by autoradiogra-
phy. The lanes represent, as indicated on the lower margin, SSCP prod-
ucts from patients P. Bl, and B2; normal donors (N); and nine CGD
patients with mutations in other regions of the gp91-phox gene ( 1-9).
-140
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-100
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Exon /
Figure 6. DNA sequence and mutations in the regulatory region of the
gp9l-phox gene. The lower case letters represent nontranslated bases;
the upper case letters in the bold box at the lower right represent the
first two codons of the open reading frame. Numbering indicates the
position 5' (negative numbers) or 3' (positive) to the transcription start
site (indicated by a vertical line). Vertical boxes at positions -57 and -
55 indicate the base changes found in the B and P families, respectively.
Horizontal boxes indicate the CCAAT and TATA box consensus se-
quences.
other X-linked CGD patients (lanes labeled with numbers 1-
9). The SSCP abnormality was not detected in any of 40 other
normal gp9l-phox genes; thus the B family mutation was asso-
ciated with the CGD phenotype of these kindreds and did not
appear to be a commonly occurring polymorphism of the gp9l-
phox gene. The normal pattern in patient P does not necessarily
imply a normal sequence in the 5' flank, since not all base
changes result in alterations of SSCP mobility. We therefore
examined the region in more detail by DNA sequencing.
Genomic sequencing demonstrated a single base change as-
sociated with CGD in each kindred: in patient B, adenine to
cytosine at base pair -57 (i.e., 57 bp upstream from the transcrip-
tion site); and in family P, thymidine to cytosine at base pair -
55 (indicated in Fig. 6). These closely adjoining mutations are
located in between the "CCAAT box" consensus sequences
and a partial "TATA box" element (see Discussion) that serve
as recognition sites for DNA-binding proteins essential for the
transcription of gp9l-phox ( 14) as well as myriad other eukary-
otic genes (48). Examination of all 13 exons of the gp9l-phox
gene by SSCP and DNA sequencing did not reveal any coding
region abnormalities in the patients.
Gel shift assays were performed to determine directly
whether the gp9l-phox promoter mutations identified in these
CGD patients affect interactions with DNA-binding proteins.
Fig. 7 shows that two specific DNA/protein complexes (indi-
cated by arrows) are formed when a 39-nucleotide region of
the gp9l-phox promoter region (-30 to -68) is used as a probe
and mixed with nuclear extract isolated from PLB985 cells
(lane 2). These two bands are specific, as they are eliminated
by competition with an - 100-fold excess of unlabeled double-
stranded homologous oligonucleotide (lane 3), but are unaf-
fected by the addition of heterologous oligonucleotide (lane 4).
Importantly, the faster migrating of these two complexes (solid
arrow) is abolished when oligonucleotides containing either of
the identified gp9l-phox promoter mutations is used as a probe
(lanes 5 and 6). The absence of the faster migrating complex
appears to enhance the slower DNA/protein complex in these
lanes.
Discussion
Multiple molecular defects within the coding region and introns
of the gp9l-phox gene can lead to X-linked CGD (15). Pre-
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Figure 7. Effect of gp9l- 1 2 3 4 5 6
phox mutations on the
association of promoter
region oligonucleotides
with DNA-binding pro-
teins. Gel shift analysis
was performed as de-
scribed in Methods, us-
ing nuclear extract from
PLB985 cells induced to S*
differentiate along the
granulocytic lineage.
Lane 1, no extract; lane
2, extract plus probe cor-
responding to the wild
type gp9l-phox pro-
moter sequence (-30 to -
68); lane 3, same as lane
2 plus addition of 20 ng
(about 1 pmol) of unla-
beled competitor double-
stranded oligonucleotide
homologous to the probe;
lane 4, same as lane 2
plus addition of 20 ng
(about 1 pmol) of heter-
ologous competitor double-stranded oligonucleotide (-1 to -39 of gp9l-
phox promoter); lane 5, extract plus oligonucleotide probe correspond-
ing to -57 promoter mutation; lane 6, extract plus oligonucleotide probe
corresponding to -55 promoter mutation.
viously reported mutations include large, multigene deletions
( 16, 49), smaller deletions and insertions leading to frameshifts
(50), missense and nonsense substitutions (18, 19), and splic-
ing errors (20, 21). However, many cases of X-linked CGD
are characterized by diminished levels of gp9l-phox mRNA
and thus could derive from mutations in regulatory regions
governing transcription of the gene (although defects in RNA
processing or stability are also possible). In this study, we have
identified two mutations at base pairs -55 and -57 in the gp91-
phox promoter region. Each is associated with X-linked CGD
with diminished expression of immunoreactive protein and
gp9l-phox mRNA, with relative preservation of transcription
initiation at an alternative start site at nucleotide 190 of the
normal cDNA sequence. Each mutation abolishes the associa-
tion of oligonucleotides corresponding to the gp9l-phox pro-
moter region with a DNA-binding protein detectable on gel
shift assay. Hence, absence of protein binding appears to be
causally related to the diminution of gp9l-phox expression and
to the development of CGD in patients carrying these promoter
mutations.
The region of gp9l-phox gene flanking sequence in which
the mutations and protein binding occur lies in between the
well-characterized consensus sequences of a duplicated CCAAT
box and a TATA box (see Fig. 6). However, the TATA box
in this promoter region does not meet minimum requirements
for TATA box binding factor: T82A97T93A85(A or T)1ooA83(A
or T)100, where the subscript indicates the percent occurrence
of the indicated nucleotide (51) . Thus, it is not clear whether the
partial consensus TATA box actually functions in transcription
initiation by RNA polymerase II, nor whether the lack of full
consensus sequence at this location contributes to the instability
of the site of transcriptional initiation in the promoter region
mutations.
Previous studies of the gp9I-phox promoter region have
identified a CCAAT displacement protein that binds to the re-
gion around the CCAAT box and interferes with CP1 binding
(14). These DNA-binding proteins, CCAAT displacement fac-
tor and CP1, respectively repress and (probably) enhance gp9I-
phox expression. The TATA box is a highly conserved sequence
motif that is critical for promoter activity and initiation of tran-
scription by RNA polymerase 11 (48).
As shown in the gel shift assay presented in Fig. 7, the
absence of the faster migrating of the two DNA-protein com-
plexes appears to enhance the amount of oligonucleotide bound
in the slower-migrating complex. This finding suggests that
these two DNA-binding proteins compete for binding. However,
no firm conclusions can be reached, as the specific activity of
the probes may differ. More detailed characterization of these
DNA-binding proteins is in progress to address this question.
The protein responsible for the faster-migrating complex is de-
tectable in cell lines representing both myeloid and nonmyeloid
hematopoietic lineages, but has not yet been found in nonhema-
topoietic cells (Eklund, E. A., and D. G. Skalnik, manuscript
submitted for publication). Thus, further investigation will also
be needed to define its role and interactions with other transcrip-
tion factors in the regulation of gp9l-phox and possibly other
myeloid-specific genes.
The data also imply a relationship between the fine structure
of the promoter region and the position for initiation of tran-
scription, presumably mediated by the DNA-binding protein(s)
that associate with the sequence mutated in these CGD kindreds.
Transcription from the alternative start site, which is a barely
detectable product of normal transcription, appears relatively
unaffected by the mutations and hence becomes a major product
in the CGD cells. Although only 190 nt downstream from the
start of the normal cDNA, the site is located in the third exon
of the gp9l-phox gene, so its position is actually 3.2 kb from
the normal site in genomic DNA, due to the additional two
intervening sequences of 1.9 and 1.1 kb. Examination of the
exon and intron sequence upstream from the alternative start
site reveals a possible SP-1 binding site in the second intron,
45 nt upstream from the nt 190 alternative transcription start
site, but no other sequence elements associated with 5' regula-
tory regions.
Translation of the transcript could theoretically yield a pro-
tein product lacking the normal gp9l-phox amino terminal se-
quence, utilizing the in-frame ATG codon at position 205 (seen
at the top of the marginal sequence in Fig. 4) or that at position
319, which is associated with a Kozak consensus sequence for
translational initiation (9). The lack of detection of such a
polypeptide on the Western blots, such as that in Fig. 1, could
indicate either instability or insufficient synthesis of such an
abnormal gene product.
The connection between the molecular effects of the muta-
tions and the cellular CGD phenotype in these kindreds remains
obscure. As presented in detail elsewhere,2 the patients have a
rare, "variant" form of the disease characterized by near normal
expression of phagocyte oxidase activity in a small subset (5-
10%) of neutrophils and no activity in the remaining cells.
We speculate that this manifestation of neutrophil heterogeneity
may reflect the utilization of different DNA binding proteins
for the enhancement or initiation of gp9l-phox transcription by
the subpopulation unaffected by the mutations.
The promoter region mutations reported in the present study
extend the inventory of molecular changes responsible for CGD
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to regulatory defects that interfere with mRNA transcription.
They have also served as "experiments of nature" that both
demonstrate the importance of the gp9l-phox promoter region
sequence between the CCAAT and TATA boxes and help detect
one or more previously unknown DNA-binding proteins that
associate with this sequence element.
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